QuartrQuartr

PEG: Net loss narrowed as clinical progress and a key legal win improved financial position, but funding needs persist

閱讀少於1分鐘

Reponex advanced clinical programs and strengthened its IP portfolio, while an arbitral award improved the outlook for recovering the Portinho S.A. receivable. The group reported a reduced net loss and improved equity, but remains pre-revenue and reliant on further financing and licensing deals.

Original document: Pharma Equity Group A/S Class A [PEG] Interim report — Aug. 14 2026

免責聲明